Sodium-glucose cotransporter 2 (SGLT2) inhibitors like empagliflozine and dapagliflozine improved symptoms and modestly reduced heart failure hospitalizations, but not death, in HFpEF trials.6,7 For more details regarding therapy of HFpEF in general the reader is referred to pertinent reviews and guidelines.8,9. The gene discussed is SLC5A2; the disease is heart failure.